Stock RGLS REGULUS THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Market Closed - Nasdaq
Other stock markets
 01:30:00 29/06/2024 am IST 		5-day change 1st Jan Change
1.785 USD -11.85% Intraday chart for Regulus Therapeutics Inc. -28.88% +39.45%
25/06 Canaccord Genuity Raises Price Target on Regulus Therapeutics to $28 From $11, Maintains Buy Rating MT
25/06 HC Wainwright Raises Regulus Therapeutics Price Target to $10 From $9, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes
PR
APPENDIX A REGULUS THERAPEUTICS INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 15, 2019 APPROVED BY THE STOCKHOLDERS: AUGUST 1, 2019 AMENDED BY THE BOARD OF DIRECTORS: APRIL 20, 2023 APPROVED BY THE STOCKHOLDERS: JUNE 13, 2023 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2024 APPROVED BY THE STOCKHOLDERS: MAY 16, 2024 - Form 8-K
PU
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
PR
Regulus: Q1 Earnings Snapshot
AQ
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
PR
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
PR
Regulus: Q4 Earnings Snapshot
AQ
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
PR
Emerging Companies: Key Developments and Investment Insights RGLS, INBS, VTAK, DYAI, TCBP
AQ
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
PR
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
PR
Regulus: Q3 Earnings Snapshot
AQ
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
PR
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
AQ
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RGLS Stock
  4. News Regulus Therapeutics Inc.
  5. Press Releases